Although the current standard technique recommended for genetic analysis in patients with AML is next-generation sequencing (NGS), it is not globally available, and capillary electrophoresis is widely used for both detecting FLT3-ITD mutations and determining the AR. The gene discussed is FLT3; the disease is acute myeloid leukemia.